小剂量地西他滨对骨髓增生异常综合征患者的疗效及对IL-13、IL-18和IL-32的影响

Influence of small-dose decitabine on curative effect,IL-13,IL-18 and IL-32 of MDS patients

目的探讨小剂量地西他滨对骨髓增生异常综合征(MDS)患者的疗效及白细胞介素-13(IL-13)、白细胞介素-18(IL-18)和白细胞介素-32(IL-32)水平的影响。方法以2015年1月—2017年1月在新乡市第一人民医院接受诊治的60例MDS患者为研究对象。根据入院的时间先后顺序分为对照组和观察组各30例。两组患者均给予地西他滨,对照组用药剂量为25 mg/(m^2?d),观察组为10 mg/(m^2?d)。比较两组治疗3个月后的疗效和不良反应发生情况以及治疗前后的IL-13、IL-18和IL-32水平。结果两组的治疗总有效率分别为80.00%和76.67%,差异无统计学意义;两组的不良反应发生情况差异不具有统计学意义,但观察组的不良反应总发生率低于对照组。治疗前,两组的IL-13、IL-18和IL-32水平差异无统计学意义;两组治疗后的IL-13水平高于且IL-18和IL-32水平低于治疗前,同组治疗前后比较差异有统计学意义(P<0.05);治疗后,观察组的IL-13水平高于对照组,且IL-18和IL-32水平低于对照组,差异有统计学意义(P<0.05)。结论地西他滨对MDS的疗效明显,剂量为10 mg/(m2?d)时临床效果好,不良反应少,可更有效改善免疫功能,并且更经济。

objective To discuss the influence of small-dose decitabine on curative effect,interleukin-13（IL-13）,interleukin-18（IL-18） and interleukin-32（IL-32） levels of myelodysplastic syndrome（MDS） patients.Methods A total of 60 MDS patientstreated in our hospital from January 2015 to January 2017 were studied and were divided into control group（30 cases） and observation group（30 cases） according to the time of admission.All patients were treated with decitabine,control group was given by 25 mg/（m^2？d） and observation group was given by 10 mg/（m^2？d）.The curative effect,IL-13,IL-18 and IL-32 levels of two groups before and after 3 months treatment were compared.Results The difference in total effective rate of two groups was not statistically significant.The difference in adverse reactions between two groups was not statistically significant,but the total incidence of adverse reactions of observation group was lower than that of control group.Before treatment,IL-13,IL-18 and IL-32 levels of two groups had no statistical difference.IL-18 and IL-32 levels of two groups after treatment were lower and IL-13 was higher than those before treatment（P〈0.05）.Conclusion The curative effect of decitabine on MDS is obvious.The curative effect of 10 mg/（m^2·d） is good.Its adverse reaction is little and more economical,can improve the immune function more effectively.